On August 1, 2022, Switzerland implemented a legal change hailed as a breakthrough. Since then, physicians have been able to prescribe medical cannabis without federal authorization. Four years later, the results are mixed: while the legal right exists, actual access to treatment remains unequal.
📑 Inhaltsverzeichnis
Patient advocacy groups report that the decisive barriers have shifted. They no longer exist in legislation but within the healthcare system itself. Anyone seeking cannabis therapy must first find a doctor willing to prescribe it, then determine who will pay for it. Neither is guaranteed.
The 2022 Reform Only Moved the Bottleneck
Before the reform, every individual treatment required a special authorization from the Federal Office of Public Health. This process was slow and bureaucratic, keeping the number of prescribing physicians small. By eliminating the approval requirement, the decision now rests solely with the treating physician.
That’s precisely the problem. Responsibility was delegated, but the necessary expertise was not. According to MEDCAN, a patient advocacy organization, they receive numerous inquiries every week from affected individuals who simply cannot find a prescribing doctor. Cannabis as medicine remains absent from standard medical education, and many practices avoid the documentation burden.
Cost Coverage Determines Whether Treatment Happens
Even more critical is the financing question. A prescription does not automatically mean insurance coverage in Switzerland. Depending on diagnosis, medication type, and insurance provider, costs may be covered by mandatory health insurance, supplemental insurance, or not at all. Long-term coverage spanning years is rare.
For chronically ill patients, this creates significant financial hardship. They often self-pay for medically prescribed therapy over extended periods. Those unable to afford it abandon treatment or seek alternatives. This isn’t a marginal problem—it affects common indications like chronic pain, spasticity from multiple sclerosis, or severe nausea during chemotherapy. Our article on cannabis for thalamus syndrome illustrates how closely certain conditions can be linked to cannabis therapy.
What Patient Advocates Demand
MEDCAN identifies four key points. There is a need for greater medical expertise in cannabis therapies, easier access to prescribing physicians, transparent and comprehensible insurance decisions, and stronger consideration of patient experiences.
The core of these demands is a binding rule for cost coverage. As long as each insurance company decides case-by-case, therapy access depends on geography, insurance provider, and personal persistence. This issue has haunted Swiss cannabis advocacy for years, as demonstrated at IG Hanf membership meetings.
Two Separate Tracks Moving Independently
Remarkably, Switzerland’s medical and regulatory approaches to cannabis develop independently. On recreational use pilot programs, the country leads internationally. Swiss cannabis pilots demonstrate that a legal market displaces the black market, and St. Gallen is running a pilot program with postal delivery.
Legislation, however, moves slowly. The responsible commission returned the cannabis regulation proposal to subcommittee. This barely affects patients anyway, since their problems lie not in narcotics law but in health insurance law. This distinction is frequently overlooked in public debate.
Frequently Asked Questions
Who can prescribe medical cannabis in Switzerland?
Since August 1, 2022, all licensed physicians may prescribe cannabis medicines. No federal authorization from the Federal Office of Public Health is required. The decision lies within the physician’s professional discretion.
Will health insurance cover the costs?
Not automatically. Cost coverage is not uniformly regulated and depends on diagnosis, medication type, and insurer. In some cases, mandatory health insurance applies; in others, supplemental insurance or no coverage at all. Long-term coverage spanning multiple years is the exception.
Which conditions are typically treated with cannabis?
Common indications include chronic pain, spasticity related to multiple sclerosis, and severe nausea during chemotherapy. There is no comprehensive legal list of approved conditions. Prescription is considered when conventional therapies prove insufficient or cause unacceptable side effects.
Why is it so difficult for patients to find a prescribing doctor?
Cannabis therapies are barely integrated into medical education and continuing education. Most practices have limited experience with dosing, medication selection, and documentation. Additionally, clarifying coverage with insurers creates substantial administrative burden.
Do Swiss recreational pilot programs relate to medical cannabis?
No. Pilot programs concern only recreational use by adults and operate under separate regulations. Medical provision follows a distinct legal framework based on physician prescription and health insurance law. Pilot program findings do not automatically improve patient access to medical cannabis.
Sources: Hanfjournal, MEDCAN association, Federal Office of Public Health (Narcotics Act amendment effective August 1, 2022).
Sollten die Krankenkassen Cannabistherapien grundsätzlich übernehmen müssen?
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
